Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Roberto Lopez-Alberola

Neurology with Special Qualifications in Child Neurology Miami, FL Medical Doctor

NPI 1417977554 CMS profile 336146

1475 Nw 12Th Ave, Box 016960 M851, Miami, FL 33136

Open in the dashboard

General payments

$30,558

151 records reported · program years 2019–2025

Research payments

$3,164

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Roberto Lopez-Alberola of Miami, FL is reported in the CMS Open Payments database as having received $30,558 across 151 general payments and $3,164 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Neurology with Special Qualifications in Child Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $8,730 38
2024 General $2,185 24
2024 Research $3,164 1
2023 General $3,274 29
2022 General $963 10
2021 General $8,354 19
2020 General $5,257 15
2019 General $1,795 16

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Roberto Lopez-Alberola
  • Neurology with Special Qualifications in Child Neurology median
  • Middle half of Neurology with Special Qualifications in Child Neurology
  • National median

In program year 2025, general payments to Roberto Lopez-Alberola were reported at $8,730. Among 1,228 Neurology with Special Qualifications in Child Neurology profiles paid that year, the median was $276 and the middle half received between $87 and $1,522.

Show as a table
Year Roberto Lopez-Alberola Neurology with Special Qualifications in Child Neurology median Middle half National median
2019 $1,795 $262 $68–$1,313 $163
2020 $5,257 $188 $46–$1,222 $114
2021 $8,354 $183 $45–$1,356 $132
2022 $963 $229 $72–$1,177 $149
2023 $3,274 $269 $93–$1,195 $160
2024 $2,185 $300 $98–$1,428 $164
2025 $8,730 $276 $87–$1,522 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Sarepta Therapeutics, Inc. $8,713 16 payments
  2. AveXis $8,092 6 payments
  3. Biogen, Inc. $4,779 16 payments
  4. LivaNova USA, Inc. $4,709 21 payments
  5. Vertex Pharmaceuticals Incorporated $1,050 2 payments
  6. Jazz Pharmaceuticals Inc. $511 18 payments
  7. Neurelis, Inc. $426 21 payments
  8. UCB, Inc. $400 8 payments
  9. Genentech USA, Inc. $267 12 payments
  10. Novo Nordisk Inc $248 2 payments
  11. Other $1,362 29 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $11,040 5 payments
  2. Honoraria $8,024 3 payments
  3. Food and Beverage $6,011 125 payments
  4. Travel and Lodging $4,483 17 payments
  5. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,000 1 payment
Products named General payments · program years 2019–2025
  1. ZOLGENSMA $8,092 6 payments
  2. Elevidys $7,525 8 payments
  3. VNS Therapy Cardiology/Vascular Diseases $3,084 14 payments
  4. VNS Therapy Neurology $1,579 5 payments
  5. Epidiolex $529 19 payments
  6. VALTOCO $426 21 payments
  7. Briviact $305 5 payments
  8. Evrysdi $267 12 payments
  9. FARXIGA $230 2 payments
  10. SPINRAZA $205 6 payments
  11. Other $1,540 35 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. AveXis $3,164 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

52

Median for Neurology: 833

Drug cost

$3,279

Median for Neurology: $202,670

Branded share of claims

0%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Lacosamide Generic 12 $2,204
Clonazepam Generic 29 $930
Risperidone Generic 11 $145

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VALTOCO
  • Neurelis, Inc. $145
$145 — —
Epidiolex
  • JAZZ PHARMACEUTICALS INC. $106
$106 — —
Evrysdi
  • Genentech USA, Inc. $76
$76 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

152 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology with Special Qualifications in Child Neurology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record